The Global Drug sales of Avastin stood at USD 2,321.70 Millions in 2022
The indicator recorded a historical decline (CAGR) of31% between 2019 to 2022 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Bevacizumab (Avastin) is a recombinant humanized monoclonal IgG1 antibody. It is formulated as injection for intravenous administration.
Mechanism of Action
Bevacizumab (Avastin) is a vascular endothelial growth factor-specific angiogenesis inhibitor. It binds VEGF-A and prevents the interaction of VEGF-A to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF-A with its receptors leads to endothelial cell proliferation and new blood vessel formation of angiogenesis. Administration of bevacizumab to colon cancer causes reduction of microvascular growth and inhibition of metastatic disease progression.
Avastin Overview
Avastin in combination with xeloda or paclitaxel is indicated for the treatment of metastatic breast cancer. In combination with cisplatin (or carboplatin) and etoposide, bevacizumab is indicated for the treatment of small-cell lung cancer. Avastin is used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer (with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease) and glioblastoma, with interferon alfa. Avastin in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer, malignant glioma. It is also indicated for the treatment of persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan. In combination with paclitaxel it is used for the treatment of platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also indicated for the treatment of cervical cancer with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy). Avastin is also indicated in combination with chemotherapy, to treat patients with recurrent ovarian cancer (Advanced Ovarian cancer). Avastin either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, and in combination with atezolizumab for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Avastin was first approved in 2004 and is sold globally including the US, the UK, France, Germany, and Japan by F. Hoffmann-La Roche Ltd and its subsidiaries. Avastin drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer